It’s important to lay strong foundations for successful drug discovery at this first stage of the process. Our integrated target identification and validation platform combines AI with expert insights, and rigorous lab validation to guide targets through robust evaluation, ready for hit discovery.
Validated, high-quality hits, delivered through integrated technologies and expert collaboration, give you a confident starting point for faster drug discovery.
Turning promising leads into clinical candidates with speed, precision, and the scientific expertise to generate high-quality data and deliver real patient impact.
Delivering integrated, modality-agnostic drug discovery to tackle complex biology, accelerate development, and advance innovative therapies with confidence.
Advancing next-generation ADCs through payload-focused design, integrated expertise, and collaborative innovation to deliver safer, more selective therapies.
Driving biologics innovation through integrated design, structural biology, and multidisciplinary expertise to accelerate next-generation therapies from concept to clinic.
Combining deep therapeutic expertise with translational insight to design strategies, reduce risk, and accelerate discovery programs toward clinical success.
Accelerating oncology drug discovery through integrated expertise, innovative modalities, and translational insight to deliver candidates with real clinical impact.
Driving immunology and inflammation drug discovery through tailored assays, translational models, and integrated expertise for faster clinical success.
Advancing CNS drug discovery through integrated models, translational biomarkers, and multidisciplinary expertise to overcome complexity and accelerate therapeutic innovation.
Designing and advancing differentiated small-molecule therapies for obesity and diabetes through integrated expertise, mechanistic insight, and translational strategies.
Inobrodib, an exciting, first-in-class oral anti-cancer drug in clinical development by CellCentric, was collaboratively designed, synthesised and supported on its pre-clinical journey by an integrated project team at Sygnature Discovery. Inobrodib is now showing promising results in Phase I and II trials for multiple myeloma and other cancer types.
It’s important to lay strong foundations for successful drug discovery at this first stage of the process. Our integrated target identification and validation platform combines AI with expert insights, and rigorous lab validation to guide targets through robust evaluation, ready for hit discovery.
Validated, high-quality hits, delivered through integrated technologies and expert collaboration, give you a confident starting point for faster drug discovery.
Turning promising leads into clinical candidates with speed, precision, and the scientific expertise to generate high-quality data and deliver real patient impact.
Delivering integrated, modality-agnostic drug discovery to tackle complex biology, accelerate development, and advance innovative therapies with confidence.
Advancing next-generation ADCs through payload-focused design, integrated expertise, and collaborative innovation to deliver safer, more selective therapies.
Driving biologics innovation through integrated design, structural biology, and multidisciplinary expertise to accelerate next-generation therapies from concept to clinic.
Combining deep therapeutic expertise with translational insight to design strategies, reduce risk, and accelerate discovery programs toward clinical success.
Accelerating oncology drug discovery through integrated expertise, innovative modalities, and translational insight to deliver candidates with real clinical impact.
Driving immunology and inflammation drug discovery through tailored assays, translational models, and integrated expertise for faster clinical success.
Advancing CNS drug discovery through integrated models, translational biomarkers, and multidisciplinary expertise to overcome complexity and accelerate therapeutic innovation.
Designing and advancing differentiated small-molecule therapies for obesity and diabetes through integrated expertise, mechanistic insight, and translational strategies.
Inobrodib, an exciting, first-in-class oral anti-cancer drug in clinical development by CellCentric, was collaboratively designed, synthesised and supported on its pre-clinical journey by an integrated project team at Sygnature Discovery. Inobrodib is now showing promising results in Phase I and II trials for multiple myeloma and other cancer types.
We deliver validated, high-quality hits through integrated technologies and expert collaboration, giving you a confident starting point for faster, smarter drug discovery.
Whether you’re tackling a novel target or refining a known pathway, we’ll build our hit identification approach around your goals.
We combine strategic insight, cutting-edge technologies, and collaborative expertise to deliver hits that move your program forward faster, smarter, and with greater confidence.
HIT SYNERGY is Sygnature Discovery’s integrated hit identification platform for today’s most challenging targets. It brings together multiple advanced screening technologies to rapidly generate high-quality, structurally diverse hits tailored to emerging target classes. These well-characterized hits provide a strong foundation for our experienced drug discovery teams to advance your compound toward candidate selection.
At the core of our hit identification process is a strategy designed for precision and impact. We begin with AI-driven literature analysis to uncover precedent for your target or related targets. This insight allows our expert teams to craft a hit-finding strategy with the highest probability of success.
We apply a spectrum of modern methodologies, tailored to your budget and timeline, that can run in parallel or independently. Most projects span 2 to 6 months, delivering validated hits that support confident decision-making and downstream success.
Our Expertise in Hit Identification Techniques
Success starts with high-quality reagents. Our protein sciences and cell biology teams provide constructs and cell lines optimized for screening and downstream development.
Virtual Screening
Our in silico drug design team accelerates hit identification using protein structures or known ligands. We’ve consistently delivered hits against challenging protein classes.
We use cutting-edge platforms and curated libraries with lead-like properties, applying active learning to expand hits in the commercial chemical space.
When tools are limited and targets are poorly understood, affinity-based screening identifies novel ligands. These can serve as ‘bait’ in degrader strategies or be further characterized for known interactions.
Our proprietary fragment library emphasizes diversity and sociability. Combined with biophysics, crystallography, and structure-based design, we turn fragments into potent leads.
In drug discovery, strategy is everything. A comprehensive survey of your target’s hit-finding landscape sets the stage for success. A well-defined roadmap shortens optimization timelines and boosts your candidate’s trajectory.
Why Choose Sygnature Discovery for Hit Identification?
Sygnature Discovery is more than a service, it’s a partnership. With decades of experience, our hit-finding team consistently delivers validated hits that set the stage for transformative hit-to-lead and lead optimization programs.
Case Studies
Trusted by customers worldwide
Our customers tell us that we act as an extension of their team and provide high quality expertise at every stage of the drug discovery process. Whether we’re supporting you through the entire process, or just a part of it, our goal isn’t simply to move you to the next stage it’s to lay the foundations for a successfully marketed drug.
From Lead to Pre-Candidate Nomination in 18 Months
Progressing from lead to pre candidate nomination in less than half the industry standard timeline, this program shows how connected scientific teams and real time insight can accelerate complex discovery.
Many intriguing drug discovery programmes begin life at start-up biotech companies. Yet at the outset, these new organisations rarely have the resources or laboratory set-up immediately available to turn their ground-breaking ideas into a new medicine.
Rapid creation of ideas using generative AI (GenAI) with Iktos Makya
Leading generative artificial intelligence (GenAI) algorithms for de novo design are being used routinely within our medicinal chemistry programmes to enable rapid idea generation to address project objectives.
Fragment-based hit discovery for the epigenetic target, BRD3
Fragment-based drug discovery allows a wide section of chemical space to be interrogated with a relatively small but diverse library of small molecules.
Helicases have been implicated in the progression of microsatellite instability-high (MSI-H) tumours and therefore represent…
Posters
Related Solutions
We bring together a dynamic blend of new talent and experienced pharmaceutical industry experts from a round the world, delivering excellence across every stage of discovery.
Integrated hit identification using HTS, fragment screening, and advanced automation delivering high-quality starting points for successful drug discovery.
When tools are limited and targets are poorly understood, affinity-based screening identifies novel ligands. These can serve as ‘bait’ in degrader strategies or be further characterized for known interactions.
From high -quality starting points to optimized leads, we unite fragment screening, structural biology, computational chemistry and medicinal chemistry to keep your program moving forward .
Clinically focused medicinal chemistry combining design excellence, AI-driven insight, and collaborative expertise to deliver molecules aligned with your goals.
Delivering co-located, multidisciplinary drug discovery programs that combine speed, precision, and scientific rigor to advance candidates with confidence.
